A Phase 2a Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole IR, Given With Ondansetron in Patients With Major Depressive Disorder
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Ondansetron (Primary) ; Pramipexole (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Chase Pharmaceuticals
- 05 Dec 2018 Planned End Date changed from 30 Dec 2018 to 30 Jan 2019.
- 05 Dec 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Jan 2019.
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.